Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POD1UM-204: Retifanlimab Alone and in Combination in Advanced or Metastatic Endometrial Cancer
2020-000496-20Phase 2Active
- Sponsor
- Incyte
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of retifanlimab in endometrial cancer (EC) (3 arms), sponsored by Incyte. Primary endpoint: Objective response rate (Group A). Started Sep 2020; status: active.
02
Drugs
retifanlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2020-000496-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000496-20.